Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05047601 · ClinicalTrials.gov registry record · Phase 2
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 2,954
- Enrollment target
NCT05047601 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 2,954 participants.
The verdict
NCT05047601, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 2,954 participants
- Enrollment target
Study Summary
The purpose of this clinical trial is to learn whether the study medicine prevent symptoms of COVID-19 in adults who have been exposed to household member(s) with a confirmed symptomatic COVID-19 infection. All participants in the study will receive treatment for COVID-19 as needed, based on their regular doctor's recommendation. Two-thirds of participants will also receive two study medicines (PF-07321332 and ritonavir) by mouth twice a day for either five or ten days. We will compare the experiences of people receiving the study medicines to those of the people who do not. This will help us determine if the study medicines are safe and effective
Interventions
- DRUG Ritonavir
- DRUG PF-07321332
- DRUG Placebo for PF-07321332
- DRUG Placebo for Ritonavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,954 participants |
| Start Date | 2021-09-09 |
| Est. Completion | 2022-04-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05047601
The ClinicalTrials.gov registry entry for NCT05047601 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 2,954 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Ritonavir is the first listed.
NCT05047601 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05047601 about?
NCT05047601 is a clinical study titled "A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection". The purpose of this clinical trial is to learn whether the study medicine prevent symptoms of COVID-19 in adults who have been exposed to household member(s) with a confirmed symptomatic COVID-19 infection. All participants in the study will receive treatment for COVID-19 as needed, based on their ...
What is the current status of trial NCT05047601?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 2,954 participants. The study started on 2021-09-09. Estimated completion is 2022-04-12.
What interventions are being tested in trial NCT05047601?
The interventions under investigation include: Ritonavir (DRUG), PF-07321332 (DRUG), Placebo for PF-07321332 (DRUG), Placebo for Ritonavir (DRUG).
Who is sponsoring clinical trial NCT05047601?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.